B+
Bull case
33%
Probability
Target price
$1.08
-81.3% vs current
DMAC
DiaMedica TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
33%
Probability
Target price
$0.57
-90.1% vs current
B-
Bear case
33%
Probability
Target price
$0.17
-97.1% vs current
AI sentiment snapshot
Latest data as of 2025-12-13
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market tone is cautious-to-negative with primary focus on cash runway and binary trial outcomes; investors price in dilution risk while some speculative interest remains around licensing upside [#10-Qp12], [#PR-2025-09-12]. Overall headlines emphasize funding risk over near-term upside [#IR-press].
RankAlpha Sentiment AI - 2025-12-13
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31eventPartnership or licensing dealHigh impact
A licensing agreement with a larger biopharma partner would de-risk development and likely produce a positive re-rate [#IR-press].
2026-03-31catalystCash runway / financing needHigh impact
Smaller biotechs commonly require dilutive financings; a negative financing event would drive a rapid downside [#10-Qp12].
2026-06-30eventClinical data readouts for lead programsHigh impact
Potential mid-stage or exploratory clinical readouts for DM199/DMA-001 could materially move valuation if efficacy/safety surprises [#10-Qp12], [#PR-2025-09-12].
Recommendation
N/A
No formal recommendation provided.
As of 2025-12-13 • Updated nightlySource: Internal modelMethodology